1. Home
  2. SAVA vs RCUS Comparison

SAVA vs RCUS Comparison

Compare SAVA & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAVA
  • RCUS
  • Stock Information
  • Founded
  • SAVA 1998
  • RCUS 2015
  • Country
  • SAVA United States
  • RCUS United States
  • Employees
  • SAVA N/A
  • RCUS N/A
  • Industry
  • SAVA Biotechnology: Pharmaceutical Preparations
  • RCUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • SAVA Health Care
  • RCUS Health Care
  • Exchange
  • SAVA Nasdaq
  • RCUS Nasdaq
  • Market Cap
  • SAVA 1.3B
  • RCUS 1.4B
  • IPO Year
  • SAVA N/A
  • RCUS 2018
  • Fundamental
  • Price
  • SAVA $26.91
  • RCUS $15.72
  • Analyst Decision
  • SAVA Strong Buy
  • RCUS Buy
  • Analyst Count
  • SAVA 3
  • RCUS 12
  • Target Price
  • SAVA $111.50
  • RCUS $34.50
  • AVG Volume (30 Days)
  • SAVA 1.3M
  • RCUS 932.9K
  • Earning Date
  • SAVA 11-07-2024
  • RCUS 11-06-2024
  • Dividend Yield
  • SAVA N/A
  • RCUS N/A
  • EPS Growth
  • SAVA N/A
  • RCUS N/A
  • EPS
  • SAVA N/A
  • RCUS N/A
  • Revenue
  • SAVA N/A
  • RCUS $263,000,000.00
  • Revenue This Year
  • SAVA N/A
  • RCUS $112.97
  • Revenue Next Year
  • SAVA N/A
  • RCUS N/A
  • P/E Ratio
  • SAVA N/A
  • RCUS N/A
  • Revenue Growth
  • SAVA N/A
  • RCUS 119.17
  • 52 Week Low
  • SAVA $8.79
  • RCUS $13.50
  • 52 Week High
  • SAVA $42.20
  • RCUS $20.31
  • Technical
  • Relative Strength Index (RSI)
  • SAVA 51.05
  • RCUS 43.78
  • Support Level
  • SAVA $25.00
  • RCUS $15.03
  • Resistance Level
  • SAVA $28.18
  • RCUS $18.98
  • Average True Range (ATR)
  • SAVA 1.81
  • RCUS 1.02
  • MACD
  • SAVA 0.07
  • RCUS -0.04
  • Stochastic Oscillator
  • SAVA 62.39
  • RCUS 20.07

About SAVA Cassava Sciences Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: